NRG3 gene is associated with the risk and age at onset of Alzheimer disease
- 399 Downloads
The Neuregulin 3 (NRG3) gene at 10q22–q24 has been implicated in multiple psychiatric traits such as cognitive impairment. We therefore hypothesized that NRG3 gene polymorphisms may play a role in Alzheimer disease (AD). This present study explored the association of NRG3 with the age at onset (AAO) of AD and the risk of developing AD. Secondary data analysis of 257 single-nucleotide polymorphisms (SNPs) in NRG3 gene was performed in 806 Alzheimer’s disease patients and 782 controls using logistic regression and linear regression analyses. Eight SNPs were associated with the risk of AD (p < 0.05), while linear regression analysis showed 33 SNPs associated with the AAO of AD (p < 0.05). Two-SNP haplotype analyses based on UNPHASED revealed that the G–C haplotype from rs17685233 and rs17101017 was significantly associated with AD (p = 0.0031) and the A–G haplotype from rs504522 and rs474018 as well as the A–G haplotype from rs504522 and rs2483295 were more significantly associated with the AAO of AD (p = 6.72 × 10−5). Using an independent family-based sample, we found one SNP rs11192423 associated with AAO both in the case–control sample (p = 0.0155) and in the family sample (p = 0.0166). In addition, we observed nominally significant associations with AD and AAO for several flanking SNPs (p < 0.05). This is the first study demonstrating that genetic variants in the NRG3 gene play a role in AD. Our results also revealed that SNPs in the NRG3 genes were more strongly associated with AAO of AD.
KeywordsAlzheimer disease Age at onset NRG3 gene Single-nucleotide polymorphisms
We acknowledge the NIH GWAS Data Repository, the Contributing Investigator(s) who contributed the phenotype data and DNA samples from his/her original study and the primary funding organization that supported the contributing study “Multi-Site Collaborative Study for Genotype–Phenotype Associations in Alzheimer’s disease and longitudinal follow-up of Genotype–Phenotype Associations in Alzheimer’s disease and Neuroimaging component of Genotype–Phenotype Associations in Alzheimer’s disease” and “National Institute on Aging—Late Onset Alzheimer’s Disease Family Study: Genome-Wide Association Study for Susceptibility Loci”. The genotypic and associated phenotypic data used in the study, “Multi-Site Collaborative Study for Genotype–Phenotype Associations in Alzheimer’s Disease (GenADA)” were provided by the GlaxoSmithKline, R&D Limited. The datasets used for analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number phs000219.v1.p1. Funding support for the “Genetic Consortium for Late Onset Alzheimer’s Disease” was provided through the Division of Neuroscience, NIA. The Genetic Consortium for Late Onset Alzheimer’s Disease includes a genome-wide association study funded as part of the Division of Neuroscience, NIA. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by Genetic Consortium for Late Onset Alzheimer’s Disease. The datasets used for analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000168.v1.p1.
- Alzheimer’s-Association, Thies W, Bleiler L (2011) Alzheimer’s disease facts and figures. Alzheimer’s Dement 7(2):208–244. doi:10.1016/j.jalz.2011.02.004
- Fallin MD, Lasseter VK, Wolyniec PS, McGrath JA, Nestadt G, Valle D, Pulver AE (2003) Genomewide linkage scan for schizophrenia susceptibility loci among Ashkenazi Jewish families shows evidence of linkage on chromosome 10q22. Am J Hum Genet 73(3):601–611. doi:10.1086/378158 PubMedCentralPubMedCrossRefGoogle Scholar
- Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, van Duijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278(16):1349–1356PubMedCrossRefGoogle Scholar
- Kao WT, Wang Y, Kleinman JE, Lipska BK, Hyde TM, Weinberger DR, Law AJ (2010) Common genetic variation in Neuregulin 3 (NRG3) influences risk for schizophrenia and impacts NRG3 expression in human brain. Proc Natl Acad Sci USA 107(35):15619–15624. doi:10.1073/pnas.1005410107 PubMedCrossRefGoogle Scholar
- Meier S, Strohmaier J, Breuer R, Mattheisen M, Degenhardt F, Mühleisen TW, Schulze TG, Nöthen MM, Cichon S, Rietschel M, Wüst S (2013) Neuregulin 3 is associated with attention deficits in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol 16(3):549–556. doi:10.1017/S1461145712000697 Google Scholar
- Piacentini S, Polimanti R, Squitti R, Mariani S, Migliore S, Vernieri F, Fuciarelli M (2012) GSTO1*E155del polymorphism associated with increased risk for late-onset Alzheimer’s disease: association hypothesis for an uncommon genetic variant. Neurosci Lett 506(2):203–207. doi:10.1016/j.neulet.2011.11.005 PubMedCrossRefGoogle Scholar
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90(5):1977–1981PubMedCrossRefGoogle Scholar
- Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R, National Institute on Aging Late-Onset Alzheimer’s Disease Family Study, Group (2010) Assessment and familial aggregation of psychosis in Alzheimer’s disease from the National Institute on Aging Late Onset Alzheimer’s Disease Family Study. Brain 133(Pt 4):1155–1162. doi:10.1093/brain/awq001 PubMedCrossRefGoogle Scholar